AU2013301368A1 - Method for the direct detection of Mycobacterium tuberculosis - Google Patents
Method for the direct detection of Mycobacterium tuberculosis Download PDFInfo
- Publication number
- AU2013301368A1 AU2013301368A1 AU2013301368A AU2013301368A AU2013301368A1 AU 2013301368 A1 AU2013301368 A1 AU 2013301368A1 AU 2013301368 A AU2013301368 A AU 2013301368A AU 2013301368 A AU2013301368 A AU 2013301368A AU 2013301368 A1 AU2013301368 A1 AU 2013301368A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- esat
- human
- alexa fluor
- products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 241000187479 Mycobacterium tuberculosis Species 0.000 title claims abstract description 6
- 238000001514 detection method Methods 0.000 title claims description 17
- 238000000684 flow cytometry Methods 0.000 claims abstract description 12
- 238000011246 intracellular protein detection Methods 0.000 claims abstract description 9
- 239000013060 biological fluid Substances 0.000 claims abstract description 7
- 239000006285 cell suspension Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 43
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 33
- 239000000047 product Substances 0.000 claims description 19
- 108010004729 Phycoerythrin Proteins 0.000 claims description 13
- 108010004469 allophycocyanin Proteins 0.000 claims description 12
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- AVEQMYZAGPYSNN-UHFFFAOYSA-N 6,8-difluoro-7-hydroxychromen-2-one Chemical class C1=CC(=O)OC2=C(F)C(O)=C(F)C=C21 AVEQMYZAGPYSNN-UHFFFAOYSA-N 0.000 claims description 8
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 claims description 8
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 claims description 8
- 206010036790 Productive cough Diseases 0.000 claims description 7
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 229930002875 chlorophyll Natural products 0.000 claims description 7
- 235000019804 chlorophyll Nutrition 0.000 claims description 7
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 7
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 238000010166 immunofluorescence Methods 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 5
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 claims description 4
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 claims description 4
- 206010063045 Effusion Diseases 0.000 claims description 4
- 206010058556 Serositis Diseases 0.000 claims description 4
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 4
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 claims description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000012117 Alexa Fluor 700 Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- -1 Cascade Yellow Substances 0.000 claims description 3
- 208000002151 Pleural effusion Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- PRGGHGIYKMNFCM-UHFFFAOYSA-N acetic acid;3-(aminomethyl)chromen-2-one Chemical compound CC(O)=O.C1=CC=C2OC(=O)C(CN)=CC2=C1 PRGGHGIYKMNFCM-UHFFFAOYSA-N 0.000 claims description 3
- 210000003756 cervix mucus Anatomy 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000002825 functional assay Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229940070376 protein Drugs 0.000 claims description 2
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 201000008827 tuberculosis Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 16
- 241000304886 Bacilli Species 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 210000003714 granulocyte Anatomy 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 208000036981 active tuberculosis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 230000006054 immunological memory Effects 0.000 description 4
- 208000033353 latent tuberculosis infection Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000011998 interferon-gamma release assay Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000000680 phagosome Anatomy 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101100439262 Caenorhabditis elegans cfp-1 gene Proteins 0.000 description 2
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- IMCUVBSHZXQITN-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-5-(2-methoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino]-4-oxobutanoic acid Chemical compound S1C(NC(=O)CCC(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1CC(=O)OC IMCUVBSHZXQITN-UHFFFAOYSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 206010065048 Latent tuberculosis Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000002383 alveolar type I cell Anatomy 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- PTIUZRZHZRYCJE-UHFFFAOYSA-N cascade yellow Chemical compound C1=C(S([O-])(=O)=O)C(OC)=CC=C1C1=CN=C(C=2C=C[N+](CC=3C=C(C=CC=3)C(=O)ON3C(CCC3=O)=O)=CC=2)O1 PTIUZRZHZRYCJE-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000004695 complexes Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000004043 pneumocyte Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56933—Mycoplasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20120100415 | 2012-08-08 | ||
| GR20120100415A GR20120100415A (el) | 2012-08-08 | 2012-08-08 | Μεθοδος αμεσης ανιχνευσης του μυκοβακτηριδιου της φυματιωσης |
| PCT/GR2013/000043 WO2014023984A2 (en) | 2012-08-08 | 2013-08-08 | Method for the direct detection of mycobacterium tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013301368A1 true AU2013301368A1 (en) | 2015-02-26 |
Family
ID=49223784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013301368A Abandoned AU2013301368A1 (en) | 2012-08-08 | 2013-08-08 | Method for the direct detection of Mycobacterium tuberculosis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150204885A1 (OSRAM) |
| EP (1) | EP2882861A2 (OSRAM) |
| CN (1) | CN104755626A (OSRAM) |
| AU (1) | AU2013301368A1 (OSRAM) |
| BR (1) | BR112015002682A2 (OSRAM) |
| GR (1) | GR20120100415A (OSRAM) |
| IN (1) | IN2015DN01760A (OSRAM) |
| MX (1) | MX2015001717A (OSRAM) |
| WO (1) | WO2014023984A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105759038A (zh) * | 2016-04-15 | 2016-07-13 | 肖乐义 | 一种检测生物样品中结核分枝杆菌的免疫检测方法及试剂盒 |
| CN105717310A (zh) * | 2016-04-15 | 2016-06-29 | 肖乐义 | 一种检测白细胞中结核分枝杆菌的免疫荧光染色方法及试剂盒 |
| GR1009115B (el) * | 2016-04-22 | 2017-09-14 | Α. & Χ. Υφαντης Α.Β.Ε.Ε Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια | Προϊοντα τροφιμων με υποκαταστατο κρεατος |
| ES2950436T3 (es) | 2016-12-14 | 2023-10-10 | Becton Dickinson Co | Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto |
| US11131618B2 (en) | 2018-08-10 | 2021-09-28 | Cytek Biosciences, Inc. | Smart flow cytometers with self monitoring and self validation |
| CN109813903A (zh) * | 2019-01-29 | 2019-05-28 | 浙江省人民医院 | 基于流式细胞术检测结核特异性t细胞免疫表型用于诊断结核分枝杆菌感染的方法 |
| CN115003798B (zh) * | 2020-06-17 | 2025-08-01 | 兰迪·莱曼·阿伦 | 用于检测分析物的方法和试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2346043T3 (es) * | 2002-04-05 | 2010-10-08 | Institut Pasteur | Identificacion de las regiones rd1 y rd5 asociadas con la virulencia que permite el desarrollo de vacunas mejoradas de m. bovis bcg y m. microti. |
| EP1674868A1 (en) * | 2004-12-21 | 2006-06-28 | Chang Gung University (a university of Taiwan) | Method and device for detection of mycobacterium tuberculosis antigens in biological fluids |
| EP2335721A1 (en) * | 2009-12-21 | 2011-06-22 | Institut Pasteur | Streptavidin and Biotin-based antigen delivery system |
| WO2011138765A1 (en) * | 2010-05-06 | 2011-11-10 | University Of The Witwatersrand, Johannesburg | A method for identifying bacteria in a sample |
-
2012
- 2012-08-08 GR GR20120100415A patent/GR20120100415A/el active IP Right Grant
-
2013
- 2013-08-08 AU AU2013301368A patent/AU2013301368A1/en not_active Abandoned
- 2013-08-08 BR BR112015002682A patent/BR112015002682A2/pt not_active Application Discontinuation
- 2013-08-08 CN CN201380049951.1A patent/CN104755626A/zh active Pending
- 2013-08-08 IN IN1760DEN2015 patent/IN2015DN01760A/en unknown
- 2013-08-08 EP EP13765397.8A patent/EP2882861A2/en not_active Ceased
- 2013-08-08 WO PCT/GR2013/000043 patent/WO2014023984A2/en not_active Ceased
- 2013-08-08 US US14/420,355 patent/US20150204885A1/en not_active Abandoned
- 2013-08-08 MX MX2015001717A patent/MX2015001717A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014023984A2 (en) | 2014-02-13 |
| IN2015DN01760A (OSRAM) | 2015-05-29 |
| CN104755626A (zh) | 2015-07-01 |
| US20150204885A1 (en) | 2015-07-23 |
| MX2015001717A (es) | 2015-12-03 |
| GR20120100415A (el) | 2014-03-17 |
| EP2882861A2 (en) | 2015-06-17 |
| BR112015002682A2 (pt) | 2017-07-04 |
| WO2014023984A3 (en) | 2014-04-03 |
| GR1008136B (el) | 2014-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5805368B2 (ja) | Ｉｐ−１０に基づく免疫学的モニタリング | |
| Cooper Jr et al. | Pathology of Penicillium marneffei | |
| US20150204885A1 (en) | Method for the direct detection of mycobacterium tuberculosis | |
| Lichtner et al. | Multifunctional Analysis of CD4+ T‐Cell Response as Immune‐Based Model for Tuberculosis Detection | |
| US7785607B2 (en) | Immune diagnostic assay to diagnose and monitor tuberculosis infection | |
| Hutchinson et al. | Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection | |
| Subbian et al. | Detection of Mycobacterium tuberculosis in latently infected lungs by immunohistochemistry and confocal microscopy | |
| Paz et al. | Multidisciplinary approach in the diagnosis of acute leptospirosis in dogs naturally infected by Leptospira interrogans serogroup Icterohaemorrhagiae: A prospective study | |
| Rovina et al. | Immune response to mycobacterial infection: lessons from flow cytometry | |
| Grimm-Geris et al. | Screening for Epstein–Barr virus (EBV) infection status in university freshmen: acceptability of a gingival swab method | |
| Tang et al. | QuantiFERON-TB Gold Plus combined with HBHA-Induced IFN-γ release assay improves the accuracy of identifying tuberculosis disease status | |
| Chaturvedi et al. | Comparative evaluation of FAT, IS900 PCR and microscopy vis a vis histo-pathology for the detection of Mycobacterium avium subsp paratuberculosis infection in tissues of goats naturally died in herds endemic for Johne’s disease | |
| Janossy et al. | The role of flow cytometry in the interferon‐γ‐based diagnosis of active tuberculosis and its coinfection with HIV‐1—A technically oriented review | |
| Lim et al. | Seroprevalence of antibodies to Rickettsia typhi in the Waikato region of New Zealand | |
| ES2366492T3 (es) | Método para el diagnóstico y/o seguimiento de aspergilosis invasivas. | |
| RU2762616C1 (ru) | Способ определения и количественной оценки специфического клеточного иммунитета к антигенам S-белка вируса SARS-COV-2 | |
| Agarwal et al. | Analysis of diagnostic methods and their sensitivity test for Mycobacterium tuberculosis | |
| Braet et al. | Leprosy agents and principal methods of detection, identification, and characterization of the leprosy agents | |
| CN109030825A (zh) | 用于特异性检测结核分枝杆菌感染的蛋白Rv2031c | |
| Buldeo et al. | Pulmonary Immune‐Compartment‐Specific Interferon Gamma Responses in HIV‐Infected Individuals with Active Tuberculosis (TB) in an Area of High TB Prevalence | |
| CN121049503A (zh) | 结核感染后特异性t细胞活化检测方法及其应用 | |
| Su et al. | Assessment of Host Immune Responses to Fungal Pathogens | |
| Al Amin et al. | Study on rickettsial diseases evidenced by Weil-Felix test among febrile patients visiting a tertiary care hospital in Mymensingh | |
| Coppola et al. | Mei gaarden | |
| Amjad et al. | Comparison of GeneXpert assay and Fluorescent Microscopy for the Diagnosis of Pulmonary Tuberculosis in Narowal region |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |